NEW BRUNSWICK, N.J. — Johnson & Johnson shareholders, upset over the health giant’s battered image amid unprecedented product recalls and ethical lapses, peppered its new CEO with questions and criticism during J&J’s annual meeting Thursday.
Others among the 1,800 J&J retirees and other shareholders attending raised concerns over serious side effects of some J&J prescription medicines.
Outgoing CEO Bill Weldon, stepping down after a decade, and successor Alex Gorsky tried to reassure the audience that the company is resolving its quality problems and focused on helping patients.
No comments:
Post a Comment